FTC/TDF + EFV or LPV/R — Competitive Intelligence Brief

FTC/TDF + EFV or LPV/R (FTC/TDF + EFV or LPV/R) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (NRTI + NNRTI or NRTI + PI). Area: Infectious Disease / Virology.

phase 3 Antiretroviral combination therapy (NRTI + NNRTI or NRTI + PI) HIV reverse transcriptase, HIV protease Infectious Disease / Virology Small molecule

Target snapshot

FTC/TDF + EFV or LPV/R (FTC/TDF + EFV or LPV/R) — French National Agency for Research on AIDS and Viral Hepatitis. This combination regimen suppresses HIV replication by blocking reverse transcriptase and protease enzymes essential for viral reproduction.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
FTC/TDF + EFV or LPV/R TARGET	FTC/TDF + EFV or LPV/R	French National Agency for Research on AIDS and Viral Hepatitis	phase 3	Antiretroviral combination therapy (NRTI + NNRTI or NRTI + PI)	HIV reverse transcriptase, HIV protease
Tenofovir + emtricitabine + lopinavir/ritonavir	Tenofovir + emtricitabine + lopinavir/ritonavir	Juan A. Arnaiz	marketed	Antiretroviral combination (NRTI + protease inhibitor)	HIV reverse transcriptase, HIV protease
All licensed antiretroviral medications	All licensed antiretroviral medications	University of Minnesota	marketed	Antiretroviral agents (multiple classes: NRTIs, NNRTIs, PIs, INSTIs, entry inhibitors)	Multiple (HIV reverse transcriptase, HIV protease, HIV integrase, CCR5, CXCR4, gp120/gp41)
Symtuza® (TAF/FTC/DRV/c)	Symtuza® (TAF/FTC/DRV/c)	Fundacion SEIMC-GESIDA	marketed	Antiretroviral combination (NRTI/INSTI class with protease inhibitor)	HIV reverse transcriptase, HIV protease, CYP3A4
HIV therapy	HIV therapy	ViiV Healthcare	marketed	Antiretroviral agents (multiple classes: NRTIs, NNRTIs, PIs, INSTIs, entry inhibitors)	Multiple targets depending on specific agent (HIV reverse transcriptase, HIV protease, HIV integrase, CCR5 co-receptor, gp120/gp41 envelope proteins)
Standard-of-care Antiretroviral therapy	Standard-of-care Antiretroviral therapy	Medical Research Council	marketed	Antiretroviral combination therapy (multiple classes: NRTI, NNRTI, PI, INSTI, entry inhibitors)	HIV reverse transcriptase, HIV protease, HIV integrase, HIV envelope glycoproteins (CCR5/CXCR4 co-receptors)
Standard Triple	Standard Triple	University of Alberta	marketed	Antiretroviral combination therapy	HIV reverse transcriptase, HIV protease (depending on formulation)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (NRTI + NNRTI or NRTI + PI) class)

1. French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class